Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
NEXIEN BIOPHARMA, INC. (NXEN) had Consolidated Net Income/Loss of $-0.03M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.03M |
|
-- |
|
-- |
|
$0.01M |
|
$-0.01M |
|
$-0.02M |
|
$-0.03M |
|
$-0.03M |
|
$-0.03M |
|
$-0.03M |
|
|
Consolidated Net Income/Loss |
$-0.03M |
$-0.03M |
|
$-0.01M |
|
$-0.01M |
|
70.77M |
|
70.77M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.01M |
|
-- |
|
-- |
|
$0.01M |
|
$0.46M |
|
-- |
|
-- |
|
$0.46M |
|
$-0.45M |
|
$-0.45M |
|
$-0.45M |
|
70.77M |
|
| Cash Flow Statement Financials | |
$-0.05M |
|
-- |
|
$0.06M |
|
$0.00M |
|
$0.01M |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-- |
|
-0.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.05M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
6.68% |
|
6.68% |
|
-363.21% |
|
6.68% |
|
$-0.01 |
|
$-0.00 |
|
$-0.00 |
|